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surgical resection followed by involved-field radiotherapy plus concomitant and six cycles of maintenance
temozolomide chemotherapy. Standards of care at recurrence are much less well defined. Minorities
of patients are offered second surgery or re-irradiation, but data on a positive impact on survival from
randomized trials are lacking. The majority of patients who are eligible for salvage therapy receive
systemic treatment, mostly with nitrosourea-based regimens or, depending on availability, bevacizumab
alone or in various combinations. In clinical trials, lomustine alone has been increasingly used as a
control arm, assigning this drug a standard-of-care position in the setting of recurrent glioblastoma.
Here we review the activity of lomustine in the treatment of diffuse gliomas of adulthood in various
settings. The most compelling data for lomustine stem from three randomized trials when lomustine was
combined with procarbazine and vincristine as the PCV regimen in the newly diagnosed setting together
with radiotherapy; improved survival with PCV was restricted to patients with isocitrate dehydrogenase-
mutant tumors. No other agent with the possible exception of regorafenib has shown superior activity to
lomustine in recurrent glioblastoma, but activity is largely restricted to patients with tumors with O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation. Hematological toxicity, notably
thrombocytopenia often limits adequate exposure.
DOI: https://doi.org/10.1016/j.ctrv.2020.102029






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Weller, Michael; Le Rhun, Emilie (2020). How did lomustine become standard of care in recurrent
glioblastoma? Cancer Treatment Reviews, 87:102029.
DOI: https://doi.org/10.1016/j.ctrv.2020.102029




How did lomustine become standard of care in recurrent glioblastoma?
Michael Wellera,
⁎
, Emilie Le Rhuna,b,c,d
a Department of Neurology, Brain Tumor Center & Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
bUniversity of Lille, Inserm, U-1192, F-59000 Lille, France
c CHU Lille, Neuro-Oncology, General and Stereotaxic Neurosurgery Service, F-59000 Lille, France
dOscar Lambret Center, Neurology, F-59000 Lille, France







A B S T R A C T
Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with
age, and males are more often affected. First-line management includes maximum safe surgical resection fol-
lowed by involved-field radiotherapy plus concomitant and six cycles of maintenance temozolomide che-
motherapy. Standards of care at recurrence are much less well defined. Minorities of patients are offered second
surgery or re-irradiation, but data on a positive impact on survival from randomized trials are lacking. The
majority of patients who are eligible for salvage therapy receive systemic treatment, mostly with nitrosourea-
based regimens or, depending on availability, bevacizumab alone or in various combinations. In clinical trials,
lomustine alone has been increasingly used as a control arm, assigning this drug a standard-of-care position in
the setting of recurrent glioblastoma. Here we review the activity of lomustine in the treatment of diffuse
gliomas of adulthood in various settings. The most compelling data for lomustine stem from three randomized
trials when lomustine was combined with procarbazine and vincristine as the PCV regimen in the newly diag-
nosed setting together with radiotherapy; improved survival with PCV was restricted to patients with isocitrate
dehydrogenase-mutant tumors. No other agent with the possible exception of regorafenib has shown superior
activity to lomustine in recurrent glioblastoma, but activity is largely restricted to patients with tumors with O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation. Hematological toxicity, notably
thrombocytopenia often limits adequate exposure.
Introduction
Lomustine, also known as CCNU (chloroethyl-cyclohexyl-ni-
trosourea), is an alkylating agent of the nitrosourea family [1–3]
(Fig. 1). It is a monofunctional alkylating agent which alkylates DNA
and RNA and can cross-link DNA and thus acts in a cell cycle-dependent
and -independent manner. One of the most relevant lesions induced by
lomustine, the formation of O6-chloroethylguanine, can be reverted by
O6-methylguanine DNA methyltransferase (MGMT). Lomustine may
also inhibit enzymatic functions by carbamoylation of amino acids but
the contribution of this activity to clinical activity remains unknown. As
a lipid-soluble drug, it permeates the blood brain barrier well which a
priori made it a reasonable candidate for the chemotherapy of intrinsic
brain tumors. It is administered orally in six to eight weeks intervals,
given its delayed myelosuppressive properties with nadirs at 5 weeks
after administration.
Lomustine in recurrent glioblastoma
Table 1 summarizes data from all published randomized clinical
trials in recurrent glioblastoma that used lomustine as a control arm
[4–11]. These trials revealed a low objective response rate to lomustine
in the range of 10% and a median progression-free survival that does
not exceed 2 months. Progression-free survival at 6 months, a common
endpoint in such trials, was in the range of 20% which today is con-
sidered a benchmark for planning randomized trials in this setting. The
few trials that reported outcome by MGMT promoter methylation status
[6,8,10] revealed low activity, if at all, in patients with tumors lacking
MGMT promoter methylation.
Overall survival from randomization in all trials was in the range of
6–9 months and differences in overall survival between trials are
probably largely driven by patient selection. None of the experimental
agents was superior to lomustine with the possible exception of regor-
afenib, however, the REGOMA trial was a medium-sized phase II trial
and several prognostic factor imbalances favored the regorafenib group:
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patients were on steroids less frequently, were younger, had more often
MGMT promoter-methylated tumors, and had a longer progression-free
survival with first-line therapy. Furthermore, cross-trial comparison
indicates particularly poor outcome with lomustine in the REGOMA
trial [10]. While this observation is held as an argument against the
validity of the data from the REGOMA trial, it is still a randomized
clinical trial, and enrollment of a poor prognosis patient population is
probably a better explanation for this poorer outcome.
Quite obviously, the one trial that is missing is a simple comparison
of lomustine with placebo or best standard of care to demonstrate that
lomustine has indeed activity in recurrent glioblastoma. In that regard,
a small Belgian trial on axitinib comes closest to such a design because
the combination of lomustine with axitinib was compared with axitinib
alone [9]. Somewhat unexpectedly, this trial indicated no additional
activity of lomustine in this setting of combination with axitinib. One
may speculate whether this even reflects partially antagonistic activity
of axitinib and lomustine, either on a biochemical level or at the level of
lomustine penetration to the tumor tissue. Anyhow, this trial has re-
ceived very little attention, probably because of small sample size,
because of the mixing of axitinib-treated patients from various stages of
the trial, and because of a mixed population of patients with first and
later recurrences of glioblastoma.
Fig. 1. Chemical structure and major mode of action of the nitrosourea lomustine (adapted from [2,3]). A. Chemical structure of lomustine (1-(2-chloroethyl)-3-
cyclohexyl-1-nitrosourea). B-D. Mechanism of DNA crosslinking. Chlorethylation of guanine at the O6 site generates O6-chloroethylguanine by the active metabolite
diazohydroxide (B). Intramolecular rearrangement of O6-chloroethylguanine to N1-O6-ethenoguanine (C). Formation of a N1-guanine-N3-cytosine interstrand
crosslink (D). Carbamoylation of lysine or arginine residues and thus inactivation of proteins via the active metabolite isocyanate (E).
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Table 1
Clinical trials of CCNU in recurrent glioblastoma.
Trial/reference Response rate Progression-free
survival (PFS)
(months)






Wick et al. 2010 [4]
Randomized phase III, open label
Enzastaurin (266) 5 responses 1.5 1.28 (0.97–1.70) 11 6.6 1.20 (0.88–1.65)
Lomustine (92) 4 responses 1.6 19 7.1
REGAL
Batchelor et al. 2013 [5]
Randomized phase III, partially blinded
Cediranib (131) 1 CR, 17 PR 3.1 (2.7–4.3) 1.05 (0.74–1.50),
p = 0.90




2CR, 19 PR 4.2 (2.8–6.7) 0.76 (0.53–1.08),
p = 0.16
35 9.4 1.15 (0.77–1.72),
p = 0.50
Lomustine (65) 5 PR 2.7 (1.4–5.6) 25 9.8
BELOB
Taal et al. 2014 [6]
Randomized phase II, open
label
ORR
Bevacizumab (50) 38 (24–53) 3 (3–4) 16 (7–27) 8 (6–9)
Bevacizumab plus lomustine
(90 mg/m2) (44)
34 (20–51) 4 (3–8) 41 (26–55) 11 (8–12)
Lomustine (46) 5 (1–17) 1 (1–3) 13 (5–24) 8 (6–11)
Bevacizumab
MGMT unmethylated (24) 8 (1–23) 1
MGMT methylated (18) 33 (14–55) 0.43
(0.21–0.85)
Bevacizumab plus lomustine (90/110 mg/m2)
MGMT unmethylated (26) 23 (9–40)
MGMT methylated (11) 62 (38–79) 0.41
(0.22–0.77)
Lomustine
MGMT unmethylated (20) 0 1
MGMT methylated (23) 26 (11–45) 0.56
(0.37–0.77)
Brandes et al. 2016 [7]
Randomized phase II, partially blinded
Galunisertib (40)) 2 PR 1.8 (1.6–3.0) 15 (5–28) 8.0 (5.7–11.7) 0.93 (0.58–1.49)
Galunisertib plus lomustine
(79)
1 CR 1.8 (1.7–1.8) 6 (2–13) 6.7 (5.3–8.5) 1.13 (0.78–1.65)
Lomustine plus placebo (39) None 1.9 (1.7–1.9) 6 (1–18) 7.5 (5.6–10.3)
Wick et al. 2017 [8]
Randomized phase III, open label
Bevacizumab plus lomustine
(288)
5 CR, 103 PR 4.2 (3.7–4.3) 0.49 (0.39–0.61),
p < 0.001
9.1 (8.1–10.1) 0.95 (0.74–1.21),
p = 0.65
Lomustine (149) 1 CR, 18 PR 1.5 (1.5–2.5) 8.6 (7.6–10.4)
Bevacizumab plus lomustine
MGMT unmethylated (102) 3.0 (2.8–3.7) 12.7 (7.1–19.9) 8.0 (6.9–9.1)
MGMT methylated (78) 6.9 (5.6–8.3) 58.4 (46.9–68.7) 12.6 (10.6–16.1)
Lomustine
MGMT unmethylated (44) 1.5 (1.4–1.5) 2.3 (0.2–10.4) 7.2 (4.8–8.6)
MGMT methylated (46) 3.0 (1.6–5.1) 30.4 (18.0–43.9) 10.4 (8.3–13.5)
Duerinck et al. 2018 [9]
Randomized phase II, open label, glioblastoma at first or later relapses
Axitinib (50) 3 CR, 11 PR 2.9 (2.6–2.8) 26 (13–38) 12.4 (4.7–16.3)
Axitinib plus lomustine (29) 11 PR 3 (1.4–4.7) 24 (8–39) 11.7 (7.9–15.6)
REGOMA
Lombardi et al. 2018 [10]
Randomized phase II, open label
Regorafenib (59) 1 CR, 2 PR 2 (1.9–3.6) 0.65 (0.45–0.95) 16.9 (8.7–27.5) 7.4 (5.8–12.0) 0.50 (0.33–0.75).
p = 0.0009
Lomustine (60) 1 CR, 1 PR 1.9 (1.8–2.1) 8.3 (3.1–17.0) 5.6 (4.7–7.3)
Regorafenib
MGMT unmethylated (30) 0.43 (0.23–0.80)
p = 0.028
MGMT methylated (29) 0.57 (0.33–0.97)
p = 0.015
(continued on next page)
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Lomustine in newly diagnosed glioblastoma?
No contemporary trial has explored whether the addition of lo-
mustine to standard of care radiotherapy would improve outcome in
subsets of gliomas of adulthood. One might speculate that similar re-
sults as obtained with temozolomide in glioblastoma should also pos-
sibly be achieved with a nitrosourea compound. Yet, the disappointing
results with lomustine as part of the PCV regimen in a historical United
Kingdom trial do not support this expectation (see below) [12]. Con-
versely, the CeTeG trial renewed interest in lomustine as part of the
management in the first-line setting (see below) [13].
Lomustine as part of the PCV regimen
Undoubtedly the most convincing efficacy data for lomustine have
been generated when the drug was used in combination with another
alkylating agent, procarbazine, and the antimitotic agent, vincristine, as
the PCV protocol. This protocol was first used in unselected brain tumor
patients in 1975, based on single agent and preclinical data, and was
not felt to be superior to carmustine at the time [14]. The most com-
monly used version of PCV today includes lomustine given at 110 mg/
m2 p.o. on day 1, procarbazine given at 60 mg/m2 p.o. on days 8–21,
and vincristine given at 1.4 mg/m2 at days 8 and 29 of a six-to-eight
week cycle. Of note, two negative clinical trials conducted in the United
Kingdom used a different regimen that uses lomustine at 100 mg/m2
p.o. on day 1, procarbazine at 100 mg/m2 p.o. on days 1–10, and
vincristine at 1.5 mg/m2 on day 1 of a six week cycle [12,15]. Vin-
cristine is commonly capped at a total dose of 2 mg.
The PCV regimen has demonstrated superiority when combined
with radiotherapy over radiotherapy alone in three randomized clinical
trials of lower (II/III) WHO grade gliomas (Table 2) [12,15–18]. Sub-
group analyses from these trials allowed to conclude that PCV is most
active in 1p19q-codeleted tumors (oligodendrogliomas) followed by
isocitrate dehydrogenase (IDH) mutant astrocytomas whereas activity
in IDH wild-type tumors remains uncertain. This is because the latter
tumors were underrepresented in the three clinical trials and because
prior studies of PCV in the newly diagnosed or recurrent setting of
mostly IDH wild-type (presumably) gliomas in the United Kingdom had
not demonstrated superiority when PCV was combined with radio-
therapy over radiotherapy alone in the newly diagnosed setting, or over
temozolomide alone in the recurrent setting (Table 2). It has remained
an area of controversy to date to what extent procarbazine and vin-
cristine contribute to the efficacy of the PCV regimen.
Vincristine does not cross the blood brain barrier, accordingly, it has
been repeatedly proposed to omit this drug from the PCV regimen,
assuming that it cannot reach its target, and also because of significant
toxicity in terms of peripheral neuropathy upon prolonged use. No
clinical trial has compared PCV with a PC regimen, that has e.g., been
used in large tumors then referred to as gliomatosis cerebri [19] and the
patient numbers required to demonstrate that vincristine can be safely
omitted would probably be enormous. Yet, two retrospective case series
have not reported inferior outcome with a PC regimen as opposed to
PCV in oligodendroglial tumors [20,21].
Procarbazine is another alkylating agent chemically related to te-
mozolomide that has inferior activity in recurrent glioblastoma as a
single agent compared with temozolomide [22]. Accordingly, there was
a rationale to improve PCV by replacing procarbazine by temozolomide
and by omitting vincristine to design a novel alkylator combination for
newly diagnosed glioblastoma [23,24]. UKT-03 was a small phase II
trial that was in part designed to overcome MGMT-mediated che-
moresistance, assuming that exposure to temozolomide for five days
directly after lomustine intake might deplete MGMT and thus improve
the efficacy of lomustine. However, compared with historical controls,
this small trial appeared to indicate no benefit in MGMT promoter
unmethylated glioblastoma, but rather a strong survival signal in pa-
tients with MGMT promoter methylated glioblastoma. Accordingly, this
combination was taken forward to a randomized phase III trial, CeTeG,
in this subset of patients. While patient numbers were small and while
there were imbalances of prognostic factors of patients at three sites,
there was still overall a signal of prolonged survival for the temozolo-
mide-lomustine combination over standard of care [13]. The idea of
combing temozolomide with lomustine has also been adopted for pe-
diatric malignant gliomas) [25,26].
The efficacy signal with combining temozolomide and lomustine in
the CeTeG trial [13] suggests that there may be true synergistic activ-
ities of different alkylating agents that warrant further study [3,27].
This is because simply doubling the dose of temozolomide in the newly
diagnosed setting, as explored in the RTOG 0525 trial, had no effect at
all on progression-free or overall survival [28].
Tolerability and safety of lomustine
Lomustine is an emetogenic chemotherapeutic agent that requires
standard antiemetic agent prophylaxis which is commonly sufficiently
active. The clinically most relevant toxicities documented in clinical
trials are summarized in Table 3 [4–11]. Thrombocytopenia emerges as
the most important toxicity overall and often requires dose reductions,
delays of cycles or even discontinuation of treatment. Neutropenia and
lymphocytopenia are comparably less frequent and less severe. Despite
this toxicity profile, myelodysplastic syndromes and leukemia are rare
as sequelae of lomustine chemotherapy presumably because the limited
life expectancy of glioma patients reduces the risk of complications that
may occur years after exposure [29], yet, given the increasing use of the
PCV regimen in patients with lower WHO grade tumors with a median
survival of 15–20 years, the incidence of such delayed haematological
complications may increase.
Table 1 (continued)
Trial/reference Response rate Progression-free
survival (PFS)
(months)








van den Bent et al. 2019 [11]
Randomized phase II, open label, EGFR-amplified glioblastoma








1 PR 1.9 8.2
Abbreviations: ND no data, OS overall survival, PFS progression-free survival, TMZ temozolomide.
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Non-haematological toxicities are of less concern, although liver
toxicity remains an issue notably in combination with other potentially
hepatotoxic drugs. Pulmonary fibrosis, a potentially life threatening
toxicity associated with nitrosourea treatment, has not been docu-
mented to be a toxicity of concern in clinical trials where toxicity was
carefully documented. The absence of relevant rates of severe pul-
monary toxicity does not justify to monitor lung function in otherwise
asymptomatic patients when planning clinical trials with lomustine.
Conclusions
Lomustine probably remains the most widely used drug second only
to temozolomide in the treatment of gliomas. Despite all limitations
summarized above, it is defined as the main standard of care for re-
current glioblastoma in Europe, where bevacizumab is not approved, in
the EANO guideline [30], and also in the Adaptive Global Innovative
Learning Environment for Glioblastoma (AGILE) consortium [31]. More-
over, lomustine is likely the key component of the PCV regimen which
has become standard of care in most lower WHO grade gliomas with
IDH mutation.
There is little doubt that exposure to lomustine could be improved
in patients with lomustine-sensitive tumors like oligodendrogliomas or
MGMT promoter-methylated glioblastoma if the key toxicities where
mitigated. One such avenue would be the administration of drugs like
romiplostim, a thrombopoietin receptor agonist recently shown to
allow adequate exposure to temozolomide in patients with newly di-
agnosed glioblastoma experiencing severe thrombocytopenia [32]. For
clinical trials in recurrent glioblastoma, while lomustine remains the
standard of care, differential sample size calculations and outcome
expectations based on the rate of patients with MGMT promoter-me-
thylated tumors enrolled into the trial should be considered.
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